These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1833 related articles for article (PubMed ID: 8468505)

  • 1. Modification of human tumour and normal tissue pH during hyperthermic and normothermic antiblastic regional isolation perfusion for malignant melanoma: a pilot study.
    van de Merwe SA; van den Berg AP; Kroon BB; van den Berge AW; Klaase JM; van der Zee J
    Int J Hyperthermia; 1993; 9(2):205-17. PubMed ID: 8468505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood leakage and melphalan leakage from the perfusion circuit during regional hyperthermic perfusion for malignant melanoma.
    Hafström L; Hugander A; Jönsson PE; Westling H; Ehrsson H
    Cancer Treat Rep; 1984 Jun; 68(6):867-72. PubMed ID: 6733699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe acute regional toxicity after normothermic or 'mild' hyperthermic isolated limb perfusion with melphalan for melanoma.
    Vrouenraets BC; Kroon BB; Klaase JM; Nieweg OE; van Slooten GW; van Dongen JA
    Melanoma Res; 1995 Dec; 5(6):425-31. PubMed ID: 8589617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion.
    Liénard D; Lejeune FJ; Ewalenko P
    World J Surg; 1992; 16(2):234-40. PubMed ID: 1561804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics of melphalan leakage during hyperthermic isolation perfusion in melanoma of the limb.
    Rauschecker HF; Foth H; Michaelis HC; Horst F; Gatzemeier W; Willenbrock C; Voth E; Kahl GF
    Cancer Chemother Pharmacol; 1991; 27(5):379-84. PubMed ID: 1998997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Surgical treatment of malignant melanoma of the limbs combined with thermochemotherapy under extracorporeal circulation].
    Truchetet F; Grosshans E; Kretz JG; Bartier JC; Laplanche G
    Ann Dermatol Venereol; 1988; 115(5):573-85. PubMed ID: 3195954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose tumour necrosis factor-alpha (TNF-alpha) and melphalan in hyperthermic isolated limb perfusion. Results from a pilot study performed in the United Kingdom.
    Hill S; Thomas JM
    Melanoma Res; 1994 Mar; 4 Suppl 1():31-4. PubMed ID: 8038593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.
    Lienard D; Ewalenko P; Delmotte JJ; Renard N; Lejeune FJ
    J Clin Oncol; 1992 Jan; 10(1):52-60. PubMed ID: 1727926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hyperthermic-antiblastic isolation perfusion for advanced melanoma of the limbs. The technic, immediate results and a review of the literature].
    Decian F; Balletto N; Camerini G; Depaoli M; D'Aniello R; Ameri A; Brisighella A; Bonalumi U; Bachi V; Civalleri D
    Minerva Chir; 1990 Oct; 45(19):1227-37. PubMed ID: 2074944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale for different approaches to combined melphalan and hyperthermia in regional isolated perfusion.
    van der Zee J; Kroon BB; Nieweg OE; van de Merwe SA; Kampinga HH
    Eur J Cancer; 1997 Sep; 33(10):1546-50. PubMed ID: 9389913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results of a double perfusion schedule using high dose hyperthermia and melphalan sequentially in extensive melanoma of the lower limb.
    Noorda EM; Vrouenraets BC; Nieweg OE; Klaase JM; van der Zee J; Kroon BB
    Melanoma Res; 2003 Aug; 13(4):395-9. PubMed ID: 12883366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Isolated hyperthermic limb perfusion with melphalan and tumor necrosis factor in malignant melanoma].
    Kettelhack C; Hohenberger P; Schlag PM
    Dtsch Med Wochenschr; 1997 Feb; 122(7):177-81. PubMed ID: 9072487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temperature distribution and pH changes during hyperthermic regional isolation perfusion.
    van der Zee J; Broekmeyer-Reurink MP; van den Berg AP; van Geel BN; Jansen RF; Kroon BB; van Wijk J; Hagenbeek A
    Eur J Cancer Clin Oncol; 1989 Aug; 25(8):1157-63. PubMed ID: 2475346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma.
    Clark J; Grabs AJ; Parsons PG; Smithers BM; Addison RS; Roberts MS
    Melanoma Res; 1994 Dec; 4(6):365-70. PubMed ID: 7703715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hyperthermic-antiblastic perfusion in the treatment of tumor of the extremities].
    Di Filippo F; Cavaliere F; Anzà M; Garinei R; Rossi CR; Deraco M; Perri P; Botti C; Cigna E
    Suppl Tumori; 2002; 1(3):S35-7. PubMed ID: 12415785
    [No Abstract]   [Full Text] [Related]  

  • 17. Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion.
    Hill S; Fawcett WJ; Sheldon J; Soni N; Williams T; Thomas JM
    Br J Surg; 1993 Aug; 80(8):995-7. PubMed ID: 8402100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb.
    Skene AI; Bulman AS; Williams TR; Thomas JM; Westbury G
    Br J Surg; 1990 Jul; 77(7):765-7. PubMed ID: 2383752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group.
    Hafström L; Rudenstam CM; Blomquist E; Ingvar C; Jönsson PE; Lagerlöf B; Lindholm C; Ringborg U; Westman G; Ostrup L
    J Clin Oncol; 1991 Dec; 9(12):2091-4. PubMed ID: 1960549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperthermic regional perfusion using membrane- instead of bubble-oxygenators. An experimental and clinical study.
    van Os J; Schraffordt Koops H; Oldhoff J; Wildevuur CR
    J Cardiovasc Surg (Torino); 1989; 30(4):523-32. PubMed ID: 2777859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 92.